TC-IRC: Impact of a Transmission Checklist in Post Anesthesia Care Unit on Immediate Respiratory Complications

Sponsor
Ramsay Générale de Santé (Other)
Overall Status
Completed
CT.gov ID
NCT03972423
Collaborator
Dr. Frédéric MARTIN (Other)
560
1
16.6
33.8

Study Details

Study Description

Brief Summary

This work highlighted the beneficial role in terms of carers' satisfaction, quantity and quality of information transmitted.

Condition or Disease Intervention/Treatment Phase
  • Other: With or wiyhout a checklist

Detailed Description

Communication and information transmission problems are responsible for the majority of serious adverse events. The use of a checklist in the operating theatre has demonstrated its benefit in terms of reducing morbidity and mortality Regarding transmissions between caregivers, numerous studies have shown the great difference between the medical data of a patient in their file and the information transmitted.

The authors recommend using checklists in order to standardise transmissions. This work highlighted the beneficial role in terms of carers' satisfaction, quantity and quality of information transmitted. On the other hand, no study has looked at the reduction of immediate postoperative complications in post anaesthesia care units (PACU).

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
560 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Impact of a Transmission Checklist in Post Anesthesia Care Unit on Immediate Respiratory Complications
Actual Study Start Date :
Feb 18, 2019
Actual Primary Completion Date :
Feb 18, 2019
Actual Study Completion Date :
Jul 7, 2020

Arms and Interventions

Arm Intervention/Treatment
IRCTC group

- The IRCTC group, consisting of all patients included in the 3rd phase of the study and for whom the transmission of information in PACU is carried out using the IRCTC.

Other: With or wiyhout a checklist
The evaluation of the impact of the use of this Checklist will be done in comparison with the standard transmission practice

CONTROL group

- The CONTROL group, consisting of all patients included in the 1st phase of the study and for whom the transmission of information in PACU is carried out according to the usual practice.

Other: With or wiyhout a checklist
The evaluation of the impact of the use of this Checklist will be done in comparison with the standard transmission practice

Outcome Measures

Primary Outcome Measures

  1. arterial oxygen desaturation < 90% [event of at least 15 second duration]

    The primary endpoint is defined as the occurrence or not of arterial oxygen desaturation < 90% for more than 15 consecutive seconds in PACU.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male or Female over 18 admitted to PACU

  • Patient having understood the aims and the methods of the research

  • Patient having expressed their consent to the use of their data.

  • Subject registered with or beneficiary of a social security scheme

Exclusion Criteria:
  • Patient participating in another clinical study

  • Acute or chronic respiratory insufficiency preoperatively

  • Protected patient: adult under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision

  • Pregnant or lactating women

Contacts and Locations

Locations

Site City State Country Postal Code
1 Les Franciscaines Clinic Versailles IDF France 78000

Sponsors and Collaborators

  • Ramsay Générale de Santé
  • Dr. Frédéric MARTIN

Investigators

  • Principal Investigator: Frederic Martin, Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ramsay Générale de Santé
ClinicalTrials.gov Identifier:
NCT03972423
Other Study ID Numbers:
  • ID-RCB : 2018-A01825-50
First Posted:
Jun 3, 2019
Last Update Posted:
Nov 12, 2020
Last Verified:
May 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ramsay Générale de Santé
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 12, 2020